UY28251A1 - Uso del hidrocloruro de la base del principio activo 1-(n2-(3,5-dibromo-n-((4-(3,4-dihidro-2 (1h)- oxoquinazolin-3-il)-1-piperidinil)-carbonil)-d-tirosil)-l-lisil)-4-(4-pipperidin)-piperazina en combinación con sumatriptano para el tratamiento de la - Google Patents
Uso del hidrocloruro de la base del principio activo 1-(n2-(3,5-dibromo-n-((4-(3,4-dihidro-2 (1h)- oxoquinazolin-3-il)-1-piperidinil)-carbonil)-d-tirosil)-l-lisil)-4-(4-pipperidin)-piperazina en combinación con sumatriptano para el tratamiento de laInfo
- Publication number
- UY28251A1 UY28251A1 UY28251A UY28251A UY28251A1 UY 28251 A1 UY28251 A1 UY 28251A1 UY 28251 A UY28251 A UY 28251A UY 28251 A UY28251 A UY 28251A UY 28251 A1 UY28251 A1 UY 28251A1
- Authority
- UY
- Uruguay
- Prior art keywords
- dibromo
- piperazine
- hydrochloride
- treatment
- active principle
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a un procedimiento para el tratamiento o la prevención de dolores de cabeza, migrana o cefalea acumulada, en el que el procedimiento comprende la administración común de una cantidad terapéuticamente eficaz del hidrocloruro de la base del principio activo 1-(N2-(3,5-dibromo-N-((4-(3,4-dihidro-2(1H)-oxo-quinazolin-3 - il)-1-piperidinil)-carbonil)-D-tirosil)- L - lisil) -4- (4-piperidin) -piperazina (A) y una cantidad terapéuticamente eficaz del principio activo contra la migrana sumatriptano, o una de las sales fisiológicamente aceptables del mismo, así como la correspondiente composición farmacéutica y su producción.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10314617A DE10314617A1 (de) | 2003-04-01 | 2003-04-01 | Verwendung des Hydrochlorids der Wirkstoffbase 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin in Kombination mit Sumatriptan zur Behandlung von Migräne |
Publications (1)
Publication Number | Publication Date |
---|---|
UY28251A1 true UY28251A1 (es) | 2004-11-08 |
Family
ID=32980861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY28251A UY28251A1 (es) | 2003-04-01 | 2004-03-31 | Uso del hidrocloruro de la base del principio activo 1-(n2-(3,5-dibromo-n-((4-(3,4-dihidro-2 (1h)- oxoquinazolin-3-il)-1-piperidinil)-carbonil)-d-tirosil)-l-lisil)-4-(4-pipperidin)-piperazina en combinación con sumatriptano para el tratamiento de la |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1631282A1 (es) |
JP (1) | JP2006522044A (es) |
AR (1) | AR043793A1 (es) |
CA (1) | CA2520930A1 (es) |
CL (1) | CL2004000686A1 (es) |
DE (1) | DE10314617A1 (es) |
TW (1) | TW200501956A (es) |
UY (1) | UY28251A1 (es) |
WO (1) | WO2004087134A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005102322A1 (de) * | 2004-04-20 | 2005-11-03 | Boehringer Ingelheim International Gmbh | Verwendung eines cgrp-antagonisten in kombination mit einem serotonin-wiederaufnahme-hemmer zur behandlung von migräne |
US20110212980A1 (en) * | 2008-10-22 | 2011-09-01 | Novartis Ag | Combinations for the treatment of migraine |
EP3416618A1 (en) | 2016-02-19 | 2018-12-26 | ZP Opco, Inc. | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines |
US11660264B2 (en) | 2017-08-23 | 2023-05-30 | Emergex USA Corporation | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches |
US11660265B2 (en) | 2018-06-28 | 2023-05-30 | Emergex USA Corporation | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10139410A1 (de) * | 2001-08-17 | 2003-02-27 | Boehringer Ingelheim Pharma | Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne |
DE10206770A1 (de) * | 2002-02-19 | 2003-08-28 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096 |
-
2003
- 2003-04-01 DE DE10314617A patent/DE10314617A1/de not_active Withdrawn
-
2004
- 2004-03-26 CA CA002520930A patent/CA2520930A1/en not_active Abandoned
- 2004-03-26 JP JP2006504871A patent/JP2006522044A/ja active Pending
- 2004-03-26 EP EP04723571A patent/EP1631282A1/de not_active Withdrawn
- 2004-03-26 WO PCT/EP2004/003210 patent/WO2004087134A1/de not_active Application Discontinuation
- 2004-03-30 TW TW093108719A patent/TW200501956A/zh unknown
- 2004-03-30 CL CL200400686A patent/CL2004000686A1/es unknown
- 2004-03-31 UY UY28251A patent/UY28251A1/es not_active Application Discontinuation
- 2004-03-31 AR ARP040101065A patent/AR043793A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2006522044A (ja) | 2006-09-28 |
TW200501956A (en) | 2005-01-16 |
AR043793A1 (es) | 2005-08-10 |
DE10314617A1 (de) | 2004-10-14 |
EP1631282A1 (de) | 2006-03-08 |
CL2004000686A1 (es) | 2005-02-04 |
WO2004087134A1 (de) | 2004-10-14 |
CA2520930A1 (en) | 2004-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS51569B (en) | COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL | |
CR8102A (es) | Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa | |
ES2376043T3 (es) | Derivados de indazol para el tratamiento de enfermedades inducidas por hsp90. | |
UY27755A1 (es) | Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores. | |
UA90518C2 (ru) | Фармацевтическая композиция в форме таблетки, которая имеет улучшеное всасывание при трансбукальном введение, которая содержит наркотический активный ингредиент и амин | |
ECSP066327A (es) | Composición de fexofenadina y proceso para prepararla | |
UY30316A1 (es) | Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
DOP2005000039A (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
NO20081942L (no) | Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser | |
HN2004000232A (es) | " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden." | |
SE0401342D0 (sv) | Therapeutic compounds | |
UY27416A1 (es) | Uso de bibn4096 en combinación con otros fármacos antimigranosos para el tratamiento de migrana | |
DE602005010744D1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas | |
MX2008008556A (es) | Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias. | |
ATE529417T1 (de) | 3',4',5-trimethoxyflavonderivate als die schleimsekretion stimulierendes mittel, entsprechendes verfahren und pharmazeutische zusammensetzung, die diese enthält | |
AR063538A1 (es) | Tratamiento de la enfermedad de parkinson | |
UY28536A1 (es) | Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos. | |
PE20211818A1 (es) | Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal | |
TW200732304A (en) | Piperidine derivatives | |
UY29134A1 (es) | Sulfonamidas sustituidas por derivados de bencimidazol, composiciones que la contienen, procedimiento de preparacion y aplicaciones | |
BRPI0411324A (pt) | composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes | |
UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
AR058141A1 (es) | Composiciones topicas de n,2,3 -trimetil-2- isopropilbutamida para el alivio del dolor y metodos para usarlas | |
CY1112718T1 (el) | Ν- (2-υδροξυαιθυλ) -ν-μεθυλ-4- (κινολιν-8-υλ (1- (θειαζολ-4-υλμεθυλ) πιπεριδιν- 4 -υλιδενο) μεθυλ) βενζαμιδιο, η μεθοδος παρασκευης του καθως και η χρηση του για τη θεραπευτικη αγωγη πονου, αγχους και καταθλιψης | |
UY28251A1 (es) | Uso del hidrocloruro de la base del principio activo 1-(n2-(3,5-dibromo-n-((4-(3,4-dihidro-2 (1h)- oxoquinazolin-3-il)-1-piperidinil)-carbonil)-d-tirosil)-l-lisil)-4-(4-pipperidin)-piperazina en combinación con sumatriptano para el tratamiento de la |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20150521 |